Jacobs & Co. CA Decreases Stock Holdings in AbbVie Inc. (NYSE:ABBV)

Jacobs & Co. CA reduced its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 0.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 60,614 shares of the company’s stock after selling 312 shares during the quarter. Jacobs & Co. CA’s holdings in AbbVie were worth $10,771,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ABBV. Sage Capital Advisors llc lifted its position in shares of AbbVie by 0.7% during the fourth quarter. Sage Capital Advisors llc now owns 22,616 shares of the company’s stock worth $4,019,000 after purchasing an additional 161 shares in the last quarter. LVM Capital Management Ltd. MI increased its stake in AbbVie by 4.4% during the fourth quarter. LVM Capital Management Ltd. MI now owns 163,273 shares of the company’s stock valued at $29,014,000 after purchasing an additional 6,892 shares during the last quarter. CCM Investment Advisers LLC increased its stake in AbbVie by 1.7% during the fourth quarter. CCM Investment Advisers LLC now owns 82,244 shares of the company’s stock valued at $14,615,000 after purchasing an additional 1,371 shares during the last quarter. ORG Wealth Partners LLC increased its stake in AbbVie by 13.9% during the fourth quarter. ORG Wealth Partners LLC now owns 14,808 shares of the company’s stock valued at $2,632,000 after purchasing an additional 1,812 shares during the last quarter. Finally, Hilltop National Bank grew its position in shares of AbbVie by 2.3% during the fourth quarter. Hilltop National Bank now owns 4,736 shares of the company’s stock worth $842,000 after acquiring an additional 108 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Trading Down 2.2 %

ABBV stock traded down $3.92 during midday trading on Friday, reaching $174.58. The stock had a trading volume of 3,036,372 shares, compared to its average volume of 4,678,735. The business has a fifty day simple moving average of $179.04 and a two-hundred day simple moving average of $184.34. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. The firm has a market cap of $308.51 billion, a price-to-earnings ratio of 60.62, a PEG ratio of 1.92 and a beta of 0.58. AbbVie Inc. has a twelve month low of $153.58 and a twelve month high of $207.32.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, October 30th. The company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.92 by $0.08. The company had revenue of $14.46 billion during the quarter, compared to analyst estimates of $14.28 billion. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the previous year, the company earned $2.95 EPS. As a group, research analysts expect that AbbVie Inc. will post 10.96 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a dividend yield of 3.76%. The ex-dividend date is Wednesday, January 15th. This is a boost from AbbVie’s previous quarterly dividend of $1.55. AbbVie’s payout ratio is 227.78%.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of recent analyst reports. Citigroup decreased their target price on shares of AbbVie from $226.00 to $215.00 and set a “buy” rating for the company in a research report on Tuesday, November 12th. Argus raised shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Monday, November 4th. Wells Fargo & Company increased their price target on shares of AbbVie to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, November 19th. JPMorgan Chase & Co. dropped their price objective on AbbVie from $210.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. Finally, Barclays increased their price target on AbbVie from $200.00 to $212.00 and gave the company an “overweight” rating in a report on Monday, October 7th. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $205.50.

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the transaction, the senior vice president now owns 6,983 shares of the company’s stock, valued at $1,202,751.92. The trade was a 20.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.25% of the company’s stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.